Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Rhythm Pharmaceuticals Inc’s stock clocked out at $64.63, up 3.06% from its previous closing price of $62.71. In other words, the price has increased by $3.06 from its previous closing price. On the day, 1.06 million shares were traded.
Ratios:
To gain a deeper understanding of RYTM’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.08 and its Current Ratio is at 3.24. In the meantime, Its Debt-to-Equity ratio is 11.81 whereas as Long-Term Debt/Eq ratio is at 11.74.
On January 02, 2025, Jefferies started tracking the stock assigning a Buy rating and target price of $80.Jefferies initiated its Buy rating on January 02, 2025, with a $80 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Apr 29 ’25 when Cramer Pamela J. sold 7,031 shares for $65.09 per share. The transaction valued at 457,663 led to the insider holds 19,209 shares of the business.
Mazabraud Yann sold 6,745 shares of RYTM for $438,946 on Apr 29 ’25. The EVP, Head of International now owns 37,655 shares after completing the transaction at $65.08 per share. On Apr 29 ’25, another insider, YANN MAZZABRAUD, who serves as the Officer of the company, bought 6,745 shares for $64.41 each.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 30.65 while its Price-to-Book (P/B) ratio in mrq is 185.57.
Stock Price History:
Over the past 52 weeks, RYTM has reached a high of $68.58, while it has fallen to a 52-week low of $35.17. The 50-Day Moving Average of the stock is 14.73%, while the 200-Day Moving Average is calculated to be 19.34%.
Shares Statistics:
A total of 62.39M shares are outstanding, with a floating share count of 57.21M. Insiders hold about 9.96% of the company’s shares, while institutions hold 94.48% stake in the company.
